Penn mRNA Biology Pioneer Drew Weissman Joins RVAC's Science Advisory Board

SINGAPORE, Oct. 1, 2021 /PRNewswire/ -- RVAC Medicines  Pte. Ltd. ("RVAC"), an emerging messager RNA (mRNA) platform company in Singapore aspiring to address various diseases with unmet medical needs for emerging markets through novel vaccines and therapeutics, today announced that one of the top international pioneers in RNA biology, Dr. Drew Weissman, M.D., Ph.D., has joined its science advisory board (SAB).

Dr. Weissman, the Roberts Family Professor of Vaccine Research at the University of Pennsylvania's Perelman School of Medicine, recently received several top national and international honors in the biomedical research community in recognition of the discovery of a therapeutic technology based on the modification of mRNA that improves its properties for use in therapeutics or prophylactic applications. It is the visionary research of Dr. Weissman and Katalin Karikó, Ph.D., an adjunt professor of Neurosurgery at the University of Pennsylvania,, stemming from a groundbreaking study published in 2005, which showed that mRNA could be modiifed and then delivered into the human body to initative a protective immune response. This discovery was a foundational component of two mRNA-based COVID-19 vaccines, from Pfizer/BioNTech and Moderna, now being used to combat the ongoing global COVID-19 pandemic. Beyond COVID-19, it is believed that mRNA technology holds promise for future vaccines and treatments for a wide range of diseases including HIV and influenza, cancer, autoimmune and incurable genetic diseases.

"We are very excited and honored to have Drew join RVAC's SAB, as his deep understanding and genuine interest in continued biomedical research in mRNA will help RVAC to make new discoveries and therapeutics to treat a host of other diseases," said Sean Cao, Ph.D., Managing Director of CBC Group, Asia's largest healthcare-dedicated investment firm.

"mRNA vaccines have protected millions of people from COVID-19 and severe symptoms and hospitalizations associated with the disease," said Dr. Weissman. "The potential for mRNA technology extends far beyond COVID-19 to many other diseases."

RVAC, incubated in 2021 by CBC Group,  aims to continuously improve its mRNA platform technology through in-house R&D and collaboration with partners initially in the fields of oncology and infectious diseases, bringing much needed public health and medical infrastructure and treatment access to the emerging markets.

About RVAC Medicines

RVAC Medicines is an mRNA biopharmaceutical company founded in 2021 and headquartered in Singapore with R&D centers in Boston and Shanghai. Leveraging its mRNA technology platform and strategic partnerships, the company is building a pipeline of innovative mRNA vaccine and therapeutic candidates to treat various diseases of unmet medical needs for the emerging markets and globally. The company is led by an experienced management team that is supported by a world-renowed scientific advisory board.

About CBC

CBC Group, Asia's largest healthcare-dedicated investment firm, commits to creating value and integrating global resources. In partnering with the world's top entrepreneurs and scientists, our unique "investor-operator" approach has empowered global leading healthcare companies to widen access to affordable medical care, catalyze innovations, and improve efficiency in fulfilling unmet medical needs worldwide. Founded in 2014, CBC has a leading team of investment, industry and portfolio management professionals headquartered in Singapore with global offices in Shanghai, Beijing, Hong Kong and New York, and presence in Boston, San Diego, San Francisco, and Tokyo. CBC focuses on platform-building, buyout, credit and growth-focused opportunities across multiple core areas within the healthcare sector, including pharmaceutical and biotech, medical technology and healthcare services. For more information, please visit www.cbridgecap.com

For media enquiries, please contact cbcpr@cbridgecap.com

Tags:
Look out for further updates on our Facebook fan page!

Related Articles

  • 【網絡熱話】打工仔糧尾慳錢必食 網民熱選茶餐廳10大午餐碟頭飯

    茶餐廳是香港的重要飲食文化之一,不但食物種類多,而且價廉物美,是不少打工仔「糧尾恩物」。最近有網民在討論區列出10大茶記午餐碟頭飯,當中包括椒鹽豬扒飯、叉燒炒蛋飯、葱油雞扒飯等等,而眾望所歸的第一名則是……

  • 【政府工略】政府請外勤員 中三學歷 日薪$803

    【政府工略】通訊事務管理局辦公室最近招聘新職位 — 外勤員,以非公務員條款聘用,學歷要求不高,只需中三程度,惟該部門要求應徵者須具備以下條件,方合資格申請。按圖了解外勤員的申請詳情︰

  • 【返工血淚史】打工仔朝早返工最絕望嘅一刻係… 網民:瞓醒開眼嗰吓

    打工仔,究竟有甚麼動力驅使你上班,是愛還是責任?是窮啊!正所謂「有頭髮邊個想做癩痢」,要不是生活逼人,有誰想上班!每天幾經辛苦才從睡床中醒過來,之後又要與路面情況搏鬥。各位認為在通勤的時候,最絕望、最痛苦的是什麼事?

  • 【行業冷知識】銀行合規程序:KYC、CDD、AML傻傻分不清?

    香港作為世界舉足輕重的金融中心,銀行業機會處處。銀行工薪高糧準,是不少人夢寐以求的終身職業。銳意尋找銀行工的朋友,相信會經常遇上合規部門職位的招聘廣告,KYC、CDD、AML更「老是常出現」。究竟這三組英文字母分別代表甚麼呢?工作性質又有甚麼不同呢?

  • 【區區打工仔】商業區新貴?黃竹坑返工好唔好?

    早前黃竹坑站上蓋住宅新盤呎價創新高,加上政府銳意啟動「躍動港島南」計劃,南區成為了港島區的未來發展焦點。早於港鐵南港島線在2016年底通車前,前身為工業區的黃竹坑已漸漸轉型,成為新進商業區。現時,黃竹坑已有多座甲級寫字樓,更有監管機構、大型企業等進駐,究竟黃竹坑的配套是否足夠呢?

  • 【職場熱話】戲院工作二三事 巡院被迫睇鬼片?

    戲院一直是港人的消閒熱點,每逢周末,人頭湧湧,滿是打算藉電影消磨時間的觀眾。現時香港一張電影票動輒要70至80元,市區黃金地段更可能超過100元才有一張。不少人相信戲院員工可無限收看電影,有時候能夠在短距離碰上影視明星,甚至可以在巡院看盡男女八卦。究竟這一切想像是否與現實相符呢?有一名已於戲院工作三年的網民在網絡討論區「連登」邀請網民發問,滿足各位對戲院的好奇心。

  • 【網絡熱話】30歲搵2萬慨嘆一事無成 網民鼓勵:大器晚成

    年近30歲,不少打工仔女都會開始意識到「職場中年危機」的威脅!人工、職位到達樽頸位,缺乏繼續向上流的機會,面對前路一臉迷茫,開始懷疑自己的職途是否到此為止?面對這個困境,應該勇敢踏出舒適圈力爭上游,抑或向現實低頭,尋找工作以外的人生目標?

  • 【畢業就業】語言學畢業必定難搵工?入職宜認清學科優點

    今年畢業的大學生,絕大部分已經在暑假前完成學業,準備投身職場。在許多人眼中,文科畢業生比較難尋找工作,當中語言學畢業者更甚。在大學校園裏,語言學學生更會自嘲出身於「頹科」,畢業必定難搵工。坊間不少人對語言學存在誤解,認為此學科的畢業生能精通多國語言,但實際並非如此,而語言學更是人文學科當中最接近理科的人文科目。

  • 【家庭關係】32歲月入5萬元 每月畀3萬做家用嘆辛苦︰仲未上到車好無用

    給父母家用,是亞洲人的傳統,用作報答家人多年的養育之恩。不過香港的物價高企,而且每月的人工無法足夠對抗通脹,年輕人生活變得百上加斤。年紀越大,責任越大,最近有名自稱32歲的打工仔概嘆,雖然自己月入5萬元,但當中有3萬元用作家用,剩下的2萬元不足以應付買樓,令他非常失落,更在討論區問網民「32歲仲未上到車係咪好無用?」按圖了解該名打工仔的想法和網民意見︰

  • 【返工血淚史】日日返工搭同一班巴士但點解會越嚟越塞?原來香港每日開車嘅人只佔全港人口⋯⋯

    塞車,仿如是香港無法解決的問題,但這個問題卻越見嚴重。比較今日和五年前坐同一條巴士路線返工,車程已經可能相差十數分鐘。